Last reviewed · How we verify
CNTO 1959
CNTO 1959 is a monoclonal antibody that inhibits IL-23 signaling to reduce inflammatory immune responses.
CNTO 1959 is a monoclonal antibody that inhibits IL-23 signaling to reduce inflammatory immune responses. Used for Psoriasis, Inflammatory bowel disease.
At a glance
| Generic name | CNTO 1959 |
|---|---|
| Sponsor | Janssen Pharmaceutical K.K. |
| Drug class | IL-23 inhibitor monoclonal antibody |
| Target | IL-23 (p19 subunit) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
CNTO 1959 targets the p19 subunit of interleukin-23 (IL-23), a key cytokine involved in Th17 cell differentiation and inflammatory pathways. By blocking IL-23, the drug suppresses pathogenic T-cell responses implicated in autoimmune and inflammatory diseases. This mechanism differs from IL-12/23 dual inhibitors, offering potentially more selective anti-inflammatory activity.
Approved indications
- Psoriasis
- Inflammatory bowel disease
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- Injection site reactions
Key clinical trials
- A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis (PHASE2)
- Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients (PHASE3)
- A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis (PHASE3)
- A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (PHASE3)
- A Study of Guselkumab in Participants With Active Psoriatic Arthritis (PHASE3)
- A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease (PHASE3)
- A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants (PHASE3)
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CNTO 1959 CI brief — competitive landscape report
- CNTO 1959 updates RSS · CI watch RSS
- Janssen Pharmaceutical K.K. portfolio CI